MAGEC1: A Potential Drug Target for Cancer (G9947)

Target Name: MAGEC1

NCBI ID: G9947

MAGEC1

MAGEC1: A Potential Drug Target for Cancer

MAGEC1 (Cancer/testis antigen 7.1) is a protein that is expressed in a variety of tissues, including the brain, testes, and gastrointestinal tract. It is also a potential drug target for several diseases, including cancer. In this article, we will discuss the biology and potential drug targets of MAGEC1, as well as its potential as a biomarker for cancer.

MAGEC1 is a transmembrane protein that is expressed in a variety of tissues, including the brain, testes, and gastrointestinal tract. It is a member of the MAGEC family of antigens, which are characterized by the presence of a single transmembrane domain and the presence of a cytoplasmic tail. MAGEC1 is expressed in a variety of tissues and is involved in several different signaling pathways.

One of the most promising aspects of MAGEC1 is its potential as a drug target for cancer. Cancer is a disease that has a high mortality rate and is a major public health issue. Currently, there are few effective treatments available for cancer, which makes it important to identify new drug targets. MAGEC1 has been shown to be involved in several different signaling pathways that are involved in cancer development.

One of the key signaling pathways that MAGEC1 is involved in is the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a key factor in the development of cancer. MAGEC1 has been shown to be involved in the regulation of PI3K/Akt signaling pathway in cancer cells.

Another signaling pathway that MAGEC1 is involved in is the TGF-β signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and angiogenesis, and is also involved in the development of cancer. MAGEC1 has been shown to be involved in the regulation of TGF-β signaling pathway in cancer cells.

In addition to its involvement in these signaling pathways, MAGEC1 has also been shown to be involved in several other signaling pathways that are involved in cancer development. For example, MAGEC1 has been shown to be involved in the regulation of the NF-kappa-B signaling pathway, which is involved in inflammation and cellular signaling.

MAGEC1 has also been shown to be involved in the regulation of the PIAS/TAZ signaling pathway, which is involved in the regulation of cell survival and angiogenesis.

In conclusion, MAGEC1 is a protein that is expressed in a variety of tissues and is involved in several different signaling pathways that are involved in cancer development. As a potential drug target, MAGEC1 has the potential to be a valuable tool in the development of new treatments for cancer. Further research is needed to fully understand the biology and potential drug targets of MAGEC1.

Protein Name: MAGE Family Member C1

The "MAGEC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets